Synthetic, Enzymatically Produced DNA For Use in DNA & mRNA Vaccines
Time: 2:00 pm
day: Conference Day One
Details:
- 4bbDNA™ confers safety benefits, enables dose reduction and reduced timelines of GMP-grade material over plasmid DNA for both DNA and mRNA vaccine applications use in vaccine applications
- A collaboration with Neomatrix on neoantigen DNA cancer vaccines using hpDNA™ constructs showed meaningful immune responses and reduced tumour growth as compared to pDNA in clinically relevant models – phase I clinical trial anticipated for H125
- mRNA produced from 4basebio’s opDNA™ templates in combination with Hermes™ nanoparticle delivery system shows enhanced immune response and reduced tumour growth comparable to conventional LNP delivery systems in several mouse models
